Format

Send to

Choose Destination
See comment in PubMed Commons below
J Cyst Fibros. 2009 Jul;8(4):253-7. doi: 10.1016/j.jcf.2009.04.008. Epub 2009 May 15.

Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis.

Author information

1
CF Centers of Hadassah Medical Center, Mount Scopus, Jerusalem, Israel.

Abstract

BACKGROUND:

Allergic bronchopulmonary aspergillosis (ABPA) in patients with CF is associated with frequent exacerbations and deterioration of lung function. Oral corticosteroids are standard therapy for ABPA and are associated with severe side effects. Monthly pulses of high-dose intravenous methylprednisolone (HDIVPM) are an effective therapy for autoimmune diseases with fewer side effects compared to oral prednisone, implicating its use for patients with CF who suffer from ABPA.

METHODS:

9 patients with CF and ABPA (4 male, 5 female, ages 7-36 years) received HDIVPM (10-15 mg/kg/d), for 3 days per month, and itraconazole, until clinical and laboratory resolution of ABPA.

RESULTS:

All patients showed clinical and laboratory improvement (FEV(1) increase, serum IgE levels and total eosinophil counts decrease) and treatment was discontinued after 6-10 pulses. Adverse effects were minor and disappeared shortly after each IV pulse therapy.

CONCLUSION:

High-dose IV-pulse methylprednisolone is an effective treatment for ABPA in CF with minor side effects.

PMID:
19447081
DOI:
10.1016/j.jcf.2009.04.008
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center